STIMUFEND is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Fresenius Kabi Usa, Llc. The primary component is Pegfilgrastim.
Product ID | 65219-371_e7a3b529-fd96-4327-9611-93c3611eb6aa |
NDC | 65219-371 |
Product Type | Human Prescription Drug |
Proprietary Name | STIMUFEND |
Generic Name | Pegflilgrastim-fpgk |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2022-10-06 |
Marketing Category | BLA / |
Application Number | BLA761173 |
Labeler Name | Fresenius Kabi USA, LLC |
Substance Name | PEGFILGRASTIM |
Active Ingredient Strength | 6 mg/.6mL |
Pharm Classes | Granulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-10-06 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
STIMUFEND 97775823 not registered Live/Pending |
Fresenius Kabi Deutschland GmbH 2023-02-01 |
STIMUFEND 79184143 5070748 Live/Registered |
Fresenius Kabi Deutschland GmbH 2016-01-28 |